What's Happening?
GRAIL, Inc. has announced the results of its NHS-Galleri trial, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial, conducted in collaboration with NHS England, evaluated the Galleri multi-cancer early detection
(MCED) test. Over three years, the trial involved 142,250 participants aged 50 to 77. The results showed a 22% reduction in Stage IV cancer diagnoses in the second screening round and a 26% reduction in the third round. The Galleri test increased cancer detection rates four-fold when added to standard screening, and reduced emergency cancer diagnoses by 25%. The trial aims to detect cancers earlier, potentially allowing for curative treatment.
Why It's Important?
The findings from the NHS-Galleri trial could significantly impact cancer screening practices. By detecting cancers at earlier stages, the Galleri test offers the potential for more effective treatments and improved survival rates. This could lead to a shift in how cancer screenings are conducted, emphasizing early detection to reduce the burden of late-stage cancer. The trial's success in reducing Stage IV diagnoses highlights the potential for the Galleri test to transform cancer care, offering hope for better patient outcomes and reducing healthcare costs associated with late-stage cancer treatments.
What's Next?
GRAIL plans to continue follow-up studies to further validate the Galleri test's effectiveness. The results will be submitted for publication in a peer-reviewed journal. The company will host an analyst call to discuss the trial outcomes and future plans. As the Galleri test becomes more widely available, it could be integrated into standard cancer screening protocols, potentially leading to policy changes in cancer detection and treatment strategies.
